Dermata Therapeutics, Inc.
General ticker "DRMA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.0M (TTM average)
Dermata Therapeutics, Inc. follows the US Stock Market performance with the rate: 36.9%.
Estimated limits based on current volatility of 6.8%: low 2.70$, high 3.10$
Factors to consider:
- Total employees count: 8 as of 2021
- Top business risk factors: Insufficient funding, Intellectual property risks, Labor/talent shortage/retention, Regulatory and compliance, Operational and conduct risks
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.86$, 3.08$]
- 2025-12-31 to 2026-12-31 estimated range: [0.52$, 1.93$]
Financial Metrics affecting the DRMA estimates:
- Positive: with PPE of -0.1 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -5905.02 <= 0.33
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: 41.86 < Shareholder equity ratio, % of 44.17 <= 63.39
- Positive: Investing cash flow per share per price, % of 0 > -0.66
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term DRMA quotes
Long-term DRMA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $9.67MM | $8.04MM | $12.51MM |
| Operating Income | $-9.67MM | $-8.04MM | $-12.51MM |
| Non-Operating Income | $0.06MM | $0.25MM | $0.23MM |
| R&D Expense | $5.65MM | $4.07MM | $8.20MM |
| Income(Loss) | $-9.61MM | $-7.79MM | $-12.29MM |
| Profit(Loss)* | $-9.61MM | $-7.79MM | $-12.29MM |
| Stockholders Equity | $6.02MM | $6.36MM | $1.56MM |
| Assets | $6.94MM | $7.98MM | $3.53MM |
| Operating Cash Flow | $-8.83MM | $-6.41MM | $-11.16MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.00MM |
| Financing Cash Flow | $4.28MM | $7.61MM | $6.89MM |
| Earnings Per Share** | $-139.16 | $-401.80 | $-80.31 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.